Skip to main content
SpringerLink
Log in

S-1 plus CIK as second-line treatment for advanced pancreatic cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This study aimed to evaluate the efficacy and tolerability of S-1 (Tegafur, Gimeracil, and Oteracil Potassium Capsules) plus CIK (Cytokine-induced killer cells) in patients with advanced pancreatic cancer who had previously received gemcitabine-based therapy. In this prospective study, fifty-eight patients were randomly divided into two groups. One group (CT group) was given S-1 alone, and the other group (immuno-CT group) was given S-1 plus CIK. S-1 was administered orally twice a day at 80 mg/m2/day on days 1–21 of a 28-day cycle till disease progression or unacceptable toxicity occurred. CIK was given for one cycle of 28 days. The disease control rate for S-1 and CIK was 40.0 and 53.6 %, respectively (p = 0.621). The serum CA19-9 level decreased for more than 25 % was significantly different (33.3 and 60.7 % in CT group and immuno-CT group, respectively, p = 0.037). The median time to progression was 2.5 (95 % CI 2.3–2.8) and 2.9 (95 % CI 2.6–3.2) months (p = 0.037) for CT group and immuno-CT group, respectively. The median overall survival was 6.1 (95 % CI 5.7–6.5) and 6.6 (95 % CI 6.1–7.1) months (p = 0.09) for CT group and immuno-CT group, respectively. The difference in hematological toxicity, including leukocytopenia, anemia, and neutropenia, was insignificant between the two groups. In contrast, the differences in non-hematological toxicity, fatigue, and non-infective fever were significantly different between the two groups (p < 0.05). The S-1 plus CIK regimen was well tolerated in a second-line setting in patients with gemcitabine-refractory and advanced pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. De Moor V, Arvanitakis M, Nagy N, et al. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathological features and long term outcome related to histopathological group. Hepatogastroenterology. 2012;59:565–9.

    PubMed  Google Scholar 

  2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.

    CAS  PubMed  Google Scholar 

  3. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73. doi:10.1038/nri2216.

    Article  CAS  PubMed  Google Scholar 

  4. Gabrilovich DI. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol. 2007;8(1):2–3.

    Article  PubMed  Google Scholar 

  5. Smith BD, Kasamon YL, Kowalski J, et al. K562/GMCSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16(1):338–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-Xuorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-Xuorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–57.

    Article  CAS  PubMed  Google Scholar 

  7. Nakai Y, Isayama H, Sasaki T, et al. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol. 2010;40:774–80.

    Article  PubMed  Google Scholar 

  8. Alsamarai S, Zergebel C, Zhang J, Furuie T, Urrea PD, Saif MW. Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer. JOP. 2008;9:185–91.

    PubMed  Google Scholar 

  9. Morizane C, Okusaka T, Furuse J, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:313–9.

    Article  CAS  PubMed  Google Scholar 

  10. Todaka A, Fukutomi A, Boku N, et al. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol. 2010;40:567–72.

    Article  PubMed  Google Scholar 

  11. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008;63:313–9.

    Article  PubMed  Google Scholar 

  12. Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol. 2010; Epub ahead of print.

  13. Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes[J]. Int J Cancer. 2002;98:864–72.

    Article  CAS  PubMed  Google Scholar 

  14. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study.

  15. Okamoto M, Kasetani H, Kaji R, et al. cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother. 1998; 47:233Y239.

    Google Scholar 

  16. Okamoto M, Ohe G, Oshikawa T, et al. Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients. Anticancer Drugs. 2000; 11:165Y173.

    Google Scholar 

  17. Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol. 2007;37:114–20.

    Article  PubMed  Google Scholar 

  18. Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5- fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol. 2005;23:4031.

    Article  Google Scholar 

  19. Kim HJ, Yun J, Kim HJ, et al. Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients. Oncol Lett. 2012;3(6):1314–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  20. Morizane C, Okusaka T, Furuse J, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;63(2):313–9.

    Article  CAS  PubMed  Google Scholar 

  21. Kim MK, Lee KH, Jang BI, et al. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol. 2009;39(1):49–53.

    Article  PubMed  Google Scholar 

  22. Bauer C, Dauer M, Saraj S, et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol Immunother. 2011;60(8):1097–107.

    Article  CAS  PubMed  Google Scholar 

  23. Wong D, Ko AH, Hwang J, et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical. Pancreas. 2008;37(3):269–2674.

    Article  PubMed  Google Scholar 

  24. Maisey NR, Norman AR, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93(7):740–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Shi SB, Wang M, Niu ZX, et al. Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer. Pancreatology. 2012;12(6):475–9.

    Article  CAS  PubMed  Google Scholar 

  26. Todaka A, Fukutomi A, Boku N, et al. S-1 Monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol. 2010;40(6):567–72.

    Article  PubMed  Google Scholar 

  27. Zhong R, Teng J, Han B, et al. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011;60(10):1497–502.

    Article  CAS  PubMed  Google Scholar 

  28. Ma Y, Zhang Z, Tang L, et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy. 2012;14(4):483–93.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

No conflicts of interest exist for any author of this paper.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Shan Dong Ji Ning First People’s Hospital, Jining, 272111, People’s Republic of China

    Meng Wang

  2. Department of Internal Medicine, Shan Dong Tumor Hospital, #440 Road Jiyan, Jinan, 250117, People’s Republic of China

    Sheng-bin Shi, Jie-lin Qi, Xiao-yong Tang & Jing Tian

Authors
  1. Meng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheng-bin Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jie-lin Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-yong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jie-lin Qi.

Additional information

Meng Wang and Sheng-bin Shi have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, M., Shi, Sb., Qi, Jl. et al. S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Med Oncol 30, 747 (2013). https://doi.org/10.1007/s12032-013-0747-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0747-9

Keywords

Search

Navigation